Tatsuhiko Sato1,2, Takuya Furuta3, Yuwei Liu4, Sadahiro Naka5, Shushi Nagamori6, Yoshikatsu Kanai7, Tadashi Watabe4. 1. Nuclear Science and Engineering Center, Japan Atomic Energy Agency, Shirakata 2-4, Tokai, Ibaraki, 319-1195, Japan. sato.tatsuhiko@jaea.go.jp. 2. Research Center for Nuclear Physics, Osaka University, Suita, Japan. sato.tatsuhiko@jaea.go.jp. 3. Nuclear Science and Engineering Center, Japan Atomic Energy Agency, Shirakata 2-4, Tokai, Ibaraki, 319-1195, Japan. 4. Department of Nuclear Medicine and Tracer Kinetics, Graduate School of Medicine, Osaka University, Suita, Japan. 5. Department of Radiology, Osaka University Hospital, Suita, Japan. 6. Department of Laboratory Medicine, The Jikei University School of Medicine, Tokyo, Japan. 7. Department of Bio-system Pharmacology, Graduate School of Medicine, Osaka University, Suita, Japan.
Abstract
BACKGROUND: An individual dosimetry system is essential for the evaluation of precise doses in nuclear medicine. The purpose of this study was to develop a system for calculating not only absorbed doses but also EQDX(α/β) from the PET-CT images of patients for targeted alpha therapy (TAT), considering the dose dependence of the relative biological effectiveness, the dose-rate effect, and the dose heterogeneity. METHODS: A general-purpose Monte Carlo particle transport code PHITS was employed as the dose calculation engine in the system, while the microdosimetric kinetic model was used for converting the absorbed dose to EQDX(α/β). PHITS input files for describing the geometry and source distribution of a patient are automatically created from PET-CT images, using newly developed modules of the radiotherapy package based on PHITS (RT-PHITS). We examined the performance of the system by calculating several organ doses using the PET-CT images of four healthy volunteers after injecting 18F-NKO-035. RESULTS: The deposition energy map obtained from our system seems to be a blurred image of the corresponding PET data because annihilation γ-rays deposit their energies rather far from the source location. The calculated organ doses agree with the corresponding data obtained from OLINDA 2.0 within 20%, indicating the reliability of our developed system. Test calculations by replacing the labeled radionuclide from 18F to 211At suggest that large dose heterogeneity in a target volume is expected in TAT, resulting in a significant decrease of EQDX(α/β) for higher-activity injection. CONCLUSIONS: As an extension of RT-PHITS, an individual dosimetry system for nuclear medicine was developed based on PHITS coupled with the microdosimetric kinetic model. It enables us to predict the therapeutic and side effects of TAT based on the clinical data largely available from conventional external radiotherapy.
BACKGROUND: An individual dosimetry system is essential for the evaluation of precise doses in nuclear medicine. The purpose of this study was to develop a system for calculating not only absorbed doses but also EQDX(α/β) from the PET-CT images of patients for targeted alpha therapy (TAT), considering the dose dependence of the relative biological effectiveness, the dose-rate effect, and the dose heterogeneity. METHODS: A general-purpose Monte Carlo particle transport code PHITS was employed as the dose calculation engine in the system, while the microdosimetric kinetic model was used for converting the absorbed dose to EQDX(α/β). PHITS input files for describing the geometry and source distribution of a patient are automatically created from PET-CT images, using newly developed modules of the radiotherapy package based on PHITS (RT-PHITS). We examined the performance of the system by calculating several organ doses using the PET-CT images of four healthy volunteers after injecting 18F-NKO-035. RESULTS: The deposition energy map obtained from our system seems to be a blurred image of the corresponding PET data because annihilation γ-rays deposit their energies rather far from the source location. The calculated organ doses agree with the corresponding data obtained from OLINDA 2.0 within 20%, indicating the reliability of our developed system. Test calculations by replacing the labeled radionuclide from 18F to 211At suggest that large dose heterogeneity in a target volume is expected in TAT, resulting in a significant decrease of EQDX(α/β) for higher-activity injection. CONCLUSIONS: As an extension of RT-PHITS, an individual dosimetry system for nuclear medicine was developed based on PHITS coupled with the microdosimetric kinetic model. It enables us to predict the therapeutic and side effects of TAT based on the clinical data largely available from conventional external radiotherapy.
Entities:
Keywords:
EQDX; Individual dosimetry; Microdosimetry; Monte Carlo; Targeted alpha therapy
Authors: Clemens Kratochwil; Frank Bruchertseifer; Frederik L Giesel; Mirjam Weis; Frederik A Verburg; Felix Mottaghy; Klaus Kopka; Christos Apostolidis; Uwe Haberkorn; Alfred Morgenstern Journal: J Nucl Med Date: 2016-07-07 Impact factor: 10.057
Authors: K S Kolbert; G Sgouros; A M Scott; J E Bronstein; R A Malane; J Zhang; H Kalaigian; S McNamara; L Schwartz; S M Larson Journal: J Nucl Med Date: 1997-02 Impact factor: 10.057
Authors: George Sgouros; John C Roeske; Michael R McDevitt; Stig Palm; Barry J Allen; Darrell R Fisher; A Bertrand Brill; Hong Song; Roger W Howell; Gamal Akabani; Wesley E Bolch; A Bertrand Brill; Darrell R Fisher; Roger W Howell; Ruby F Meredith; George Sgouros; Barry W Wessels; Pat B Zanzonico Journal: J Nucl Med Date: 2010-01-15 Impact factor: 10.057